February 6, 2026 7:30am

Climbing out-of-the-hole

Earnings: Arrowhead Pharmaceuticals (ARWR) <in the Bottom line>

Pre-open Signals: 5 Positive Indications; appears to be an uplifting “prognosis” today; If you understand probabilities, the inevitable is easier to maneuver

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

 

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Thursday’s RMi Closing Bell: Whacked, bloodied and knifed … https://www.regmedinvestors.com/articles/14300     

RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719 … https://www.regmedinvestors.com/articles/14295   

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The pre-open Dow futures are UP +0.50% or (+244 points), the S&P futures are UP +0.52% or (+35 points) and the Nasdaq futures are UP +0.64% or (+158 points)

  • U.S. stock futures are traveling UP on a tear upward after multiple dives on Friday, 2/6
  • European markets opened lower,
  • Asia Pacific markets loses steam as South Korea leads downward again

 

Economic Data: a couple and a talking Fed head

  • 10:00 am             Consumer sentiment (prelim)   Feb.                       55.0        56.4
  • 12:00 pm             Fed Vice Chair Philip Jefferson speaks                                                   
  • 3:00 pm               Consumer credit              Dec.                       $8.0 billion         $4.2 billion

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed DOWN -592.58 points or -1.20%, the S&P closed DOWN -84.34 points or -1.23% while the Nasdaq closed DOWN -363.993 points or -1.59%
  • Wednesday: The Dow closed UP +259.91 points or +0.53%, the S&P closed DOWN -35.06 points or -0.51% while the Nasdaq closed DOWN -350.606 points or -1.51%
  • Tuesday: The Dow closed DOWN -166.67 points or -0.34%, the S&P closed DOWN -58.63 points or -0.84% while the Nasdaq closed DOWN -336.9222 points or -1.43%
  • Monday: The Dow closed UP +515.19 points or +1.05%, the S&P closed UP +37.41 points or +0.54% while the Nasdaq closed UP +130.292 points or +0.56%

 

  • Last week: The S&P 500 closed up +0.04% and the Nasdaq -0.2%, while the Dow dropped -0.2%.
  • The previous week: The S&P 500 was down -0.4%, the Dow -0.4% and the Nasdaq was down -0.1%.
  • January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

 

Q1/26 – Q1 February – 1 positive and 3 negative closes

  • January – 2 holiday, 2 neutral, 9 negative and 9 positive closes  

Q4 – December,

  • 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Multiple earnings next week as sector releases Qs and FY25 …

CRISPR Therapeutics (CRSP) closed down -$4.29 after Wednesday’s -$1.83 after Tuesday’s +$0.69 after Monday’s +$1.35 after Friday’s -$3.39 with a positive +$1.24 or +2.70% pre-open

IQIA Holdings (IQV) closed down -$21.58 after Wednesday’s -$1.48 after Tuesday’s -$27.54 after Monday’s +$1.01 after last Friday’s -$5.33 with a positive +$3.68 or +2.03% pre-open

Arrowhead Pharmaceuticals (ARWR) closed down -$3.42 after Wednesday’s -$4.08 after Tuesday’s -$0.86 after Monday’s +$3.67 after Friday’s + $0.21 with a positive +$2.30 or +3.56% pre-open

BioNTech (BNTX) closed down -$3.23 after Wednesday’s +$0.52 after Tuesday’s -$0.63 after Monday’s -$4.87 with a positive +$1.74 or +1.65% pre-open

Moderna (MRNA) closed down -$1.90 after Wednesday’s +$0.57 after Tuesday’s -$0.35 after Monday’s -$1.52 with a positive +$0.41 or +1% pre-open

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

Shifting … you know what that means … rangebound for weeks or months. That makes it hard to gain any traction, especially with new positions.

The stock market saw significant, broad losses Thursday, breaking key levels.

Today, Friday futures are “swelling” and leaping upward pre-open as tailwinds push the Dow, S&P 500 futures followed by Nasdaq futures.

 

Earnings: Arrowhead Pharmaceuticals (ARWR) <from last night> …

Net income of $30.811 M or +0.22 per share <missed expectation was of +$060 cents per share> , revenue of $264 M missed Street forecasts expecting $295.3 M, cash position of $201,642 M

  • Closed two concurrent public offerings with gross proceeds totaling $930,000,000 and consisting of (i) 0.00% convertible senior notes due 2032 (the "notes") and (ii) shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants);
  • Triggered a $200.0 million milestone payment from Sarepta Therapeutics, Inc., which was earned on November 20, 2025, when the Company reached the second of two prespecified enrollment targets and subsequent authorization to dose escalate in a P1/2 clinical study of SRP-1003 (formerly ARO-DM1), an investigational RNAi therapeutic for the treatment of type 1 myotonic dystrophy (DM1);
  • Announced a global licensing and collaboration agreement with Novartis, which closed on October 17, 2025, for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson’s Disease, and for other additional collaboration targets that will utilize Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform. Financial terms of the agreement include:
  • Arrowhead received a $200 million upfront payment from Novartis. Arrowhead is also eligible to receive development, regulatory, and sales milestone payments of up to $2 billion. Arrowhead is further eligible to receive tiered royalties on commercial sales up to the low double digits.

ARWR shares have fallen roughly 3% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $64.64, more than tripling in the last 12 months.

 

Since, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

  • 2/12 - Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and Ultragenyx Pharmaceuticals (RARE)
  • 2/13 – Moderna (MRNA)

 

Welcome to my world of defining the “grey’ in our universe!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

February begins …

  • Thursday closed negative with 2 incliners, 36 decliners and 2 flata
  • Wednesday closed negative with 10 incliners, 29 decliners and 1 flat
  • Tuesday closed negative with 18 incliners, 21 decliners and 1 flat              
  • Monday closed positive with 29 incliners, 10 decliners and 1 flat

January – the last week:

  • 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
  • 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
  • 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.